Gastrointest Endosc. 2016 Apr;83(4):684-98.e7. doi: 10.1016/j.gie.2016.01.007. Epub 2016 Feb 11.
Endoscopic real-time imaging of Barrett's esophagus (BE) with advanced imaging technologies enables targeted biopsies and may eliminate the need for random biopsies to detect dysplasia during endoscopic surveillance of BE. This systematic review and meta-analysis was performed by the American Society for Gastrointestinal Endoscopy (ASGE) Technology Committee to specifically assess whether acceptable performance thresholds outlined by the ASGE Preservation and Incorporation of Valuable Endoscopic Innovations (PIVI) document for clinical adoption of these technologies have been met.
We conducted meta-analyses calculating the pooled sensitivity, negative predictive value (NPV), and specificity for chromoendoscopy by using acetic acid and methylene blue, electronic chromoendoscopy by using narrow-band imaging, and confocal laser endomicroscopy (CLE) for the detection of dysplasia. Random effects meta-analysis models were used. Statistical heterogeneity was evaluated by means of I(2) statistics.
The pooled sensitivity, NPV, and specificity for acetic acid chromoendoscopy were 96.6% (95% confidence interval [CI], 95-98), 98.3% (95% CI, 94.8-99.4), and 84.6% (95% CI, 68.5-93.2), respectively. The pooled sensitivity, NPV, and specificity for electronic chromoendoscopy by using narrow-band imaging were 94.2% (95% CI, 82.6-98.2), 97.5% (95% CI, 95.1-98.7), and 94.4% (95% CI, 80.5-98.6), respectively. The pooled sensitivity, NPV, and specificity for endoscope-based CLE were 90.4% (95% CI, 71.9-97.2), 98.3% (95% CI, 94.2-99.5), and 92.7% (95% CI, 87-96), respectively.
Our meta-analysis indicates that targeted biopsies with acetic acid chromoendoscopy, electronic chromoendoscopy by using narrow-band imaging, and endoscope-based CLE meet the thresholds set by the ASGE PIVI, at least when performed by endoscopists with expertise in advanced imaging techniques. The ASGE Technology Committee therefore endorses using these advanced imaging modalities to guide targeted biopsies for the detection of dysplasia during surveillance of patients with previously nondysplastic BE, thereby replacing the currently used random biopsy protocols.
利用先进的成像技术对 Barrett 食管(BE)进行内镜实时成像,可进行靶向活检,并且可能消除在 BE 内镜监测期间检测异型增生时需要进行随机活检的必要性。美国胃肠内镜学会(ASGE)技术委员会进行了这项系统评价和荟萃分析,旨在专门评估这些技术的临床应用是否符合 ASGE 保存和采用有价值的内镜创新(PIVI)文件中概述的可接受性能阈值。
我们通过荟萃分析计算了醋酸和亚甲蓝染色的 chromoendoscopy、窄带成像的电子 chromoendoscopy 和共聚焦激光内镜检查(CLE)用于检测异型增生的 pooled 敏感性、阴性预测值(NPV)和特异性。使用随机效应荟萃分析模型。通过 I(2)统计评估统计异质性。
醋酸 chromoendoscopy 的 pooled 敏感性、NPV 和特异性分别为 96.6%(95%CI,95-98)、98.3%(95%CI,94.8-99.4)和 84.6%(95%CI,68.5-93.2)。窄带成像电子 chromoendoscopy 的 pooled 敏感性、NPV 和特异性分别为 94.2%(95%CI,82.6-98.2)、97.5%(95%CI,95.1-98.7)和 94.4%(95%CI,80.5-98.6)。基于内镜的 CLE 的 pooled 敏感性、NPV 和特异性分别为 90.4%(95%CI,71.9-97.2)、98.3%(95%CI,94.2-99.5)和 92.7%(95%CI,87-96)。
我们的荟萃分析表明,醋酸 chromoendoscopy、窄带成像电子 chromoendoscopy 和基于内镜的 CLE 的靶向活检符合 ASGE PIVI 设定的阈值,至少在具有先进成像技术专业知识的内镜医师进行时是如此。因此,ASGE 技术委员会支持使用这些先进的成像方式来指导靶向活检,以检测先前非异型增生性 BE 患者监测期间的异型增生,从而取代目前使用的随机活检方案。